Laser and Retinal Research Unit, Department of Ophthalmology, King's College Hospital, London, UK.
Eye (Lond). 2011 Dec;25(12):1612-6. doi: 10.1038/eye.2011.223. Epub 2011 Sep 16.
To define factors that determine the location and stability of fixation in patients with neovascular age-related macular degeneration (NV-AMD) treated with intravitreal ranibizumab injections.
The location and stability of fixation using microperimetry were determined in 77 eyes treated with ranibizumab for NV-AMD for at least 12 months. All patients were treated with three injections of ranibizumab 0.5 mg, 1 month apart and retreated according to predefined criteria. The fixation parameters were correlated to the visual acuity, and quantitative measures on OCT.
The location of fixation was predominantly central in 52.6%, poor central fixation in 9.2%, and predominantly eccentric fixation in 38.2%. The fixation was stable in 65%, relatively unstable in 25%, and unstable in 10%. Visual acuity was the only factor that determined the stability and location of fixation. The characteristics of fixation were not related to the macular thickness or volume as measured by OCT.
Better visual outcome ensures central and stable fixation. Quantitative measures of OCT parameters do not determine fixation. Further studies on morphological features of the macula may provide some insight into the determinants of fixation.
确定接受玻璃体内雷珠单抗注射治疗的新生血管性年龄相关性黄斑变性（NV-AMD）患者注视点位置和稳定性的决定因素。
对至少接受了 12 个月雷珠单抗治疗的 77 只 NV-AMD 眼进行微视野检查，以确定注视点位置和稳定性。所有患者均接受了三次玻璃体内注射雷珠单抗 0.5mg，间隔 1 个月，并根据预设标准进行了再次治疗。将注视点参数与视力和 OCT 的定量测量值相关联。
注视点位置主要集中在中央区的占 52.6%，中央区固视不良的占 9.2%，主要为偏心固视的占 38.2%。65%的患者注视点稳定，25%的患者注视点相对不稳定，10%的患者注视点不稳定。视力是决定注视点稳定性和位置的唯一因素。注视点的特征与 OCT 测量的黄斑厚度或体积无关。
更好的视力结果可确保中央和稳定的注视点。OCT 参数的定量测量并不能决定注视点。对黄斑形态特征的进一步研究可能会为注视点的决定因素提供一些见解。
